Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Formation of FcRγ-deficient NK cell subset associated with HCMV-reactivation in hematopoietic cell transplant recipients.
Authors
Jaewon Lee
University of California Davis, Davis, CA
Jaewon Lee, Sungjin Kim, Jeannine Scott, A. Samer Al-Homsi, Stephanie F. Williams, Marlee Muilenburg, Suyeon Hong, Walter J Esselman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Natural Killer (NK) Cells
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 131)
DOI
10.1200/JCO.2017.35.7_suppl.131
Abstract #
131
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.
First Author: Luca Rastelli
Poster
2016 ASCO Annual Meeting
Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma.
First Author: Nina Shah
Poster
2015 ASCO Annual Meeting
Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).
First Author: Chakra Pani Chaulagain
Poster
2022 ASCO Annual Meeting
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
First Author: Anthony B. El-Khoueiry